FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2936132056> ?p ?o ?g. }

• W2936132056 endingPage "374" @default.
• W2936132056 startingPage "364" @default.
• W2936132056 abstract "Endothermal techniques have proved to be effective for treatment of incompetent truncal veins. The tumescentless mechanochemical ablation (MOCA) technique has become an alternative treatment modality, but its outcome with regard to endothermal techniques is still unclear.A multicenter prospective randomized controlled trial was designed comparing MOCA with radiofrequency ablation (RFA) to treat great saphenous vein incompetence with the hypothesis that MOCA is associated with less postprocedural pain and a comparable anatomic and clinical success rate at 1-year follow-up. Disease-specific quality of life and general health-related quality of life (HRQoL) were measured using questionnaires. Inclusion was terminated prematurely because reimbursement was suspended.A total of 213 patients (46.3% of intended number of patients) were randomized, of whom 209 were treated (105 in the MOCA group and 104 in the RFA group). Overall median pain scores during the first 14 days were lower after MOCA (0.2 vs 0.5 after RFA; P = .010), although the absolute difference was small. At 30 days, similar complication numbers (MOCA, n = 62; RFA, n = 63) and HRQoL scores (Aberdeen Varicose Vein Questionnaire: MOCA, 8.9; RFA, 7.6; P = .233) were observed. Hyperpigmentation was reported in seven patients in the MOCA group and two patients in the RFA group (P = .038). In the MOCA group, there were four complete failures (3.8%) compared with none in the RFA group (P = .045), although in one patient at 1 year, the vein showed occlusion. Median 30-day Venous Clinical Severity Score (VCSS) was significantly lower at 30 days after MOCA (1.0 vs 2.0 in the RFA group; P = .001), whereas VCSS was comparable at baseline (MOCA, 4.0; RFA, 5.0; P = .155). The 1- and 2-year anatomic success rate was lower after MOCA (83.5% and 80.0%) compared with RFA (94.2% and 88.3%; P = .025 and .066), mainly driven by partial recanalizations. After 2 years of follow-up, no differences were observed in the number of complete failures. Similar clinical success rates at 1 year (MOCA, 88.7%; RFA, 93.2%; P = .315) and 2 years (MOCA, 93.0%; RFA, 90.4%; P = .699) and no differences in HRQoL scores on the Aberdeen Varicose Vein Questionnaire at 1 year (MOCA, 7.5; RFA, 7.0; P = .753) and 2 years (MOCA, 5.0%; RFA, 4.8%; P = .573) were observed. There were two cardiac serious adverse events, a ventricular fibrillation in the MOCA group (1 year) and an unstable angina in the RFA group (2 years). One deep venous thrombosis occurred in the RFA group on 1-year duplex ultrasound, without clinical sequelae.Unilateral treatment with MOCA in the short term resulted in less postoperative pain but more hyperpigmentation compared with RFA and a faster improvement in VCSS. More anatomic failures were reported after MOCA, mostly driven by partial recanalizations, but both techniques were associated with similar clinical outcomes at 1 year and 2 years." @default.
• W2936132056 created "2019-04-25" @default.
• W2936132056 creator A5004367806 @default.
• W2936132056 creator A5021753521 @default.
• W2936132056 creator A5022225942 @default.
• W2936132056 creator A5028254994 @default.
• W2936132056 creator A5029411852 @default.
• W2936132056 creator A5061498267 @default.
• W2936132056 creator A5061637031 @default.
• W2936132056 creator A5065145747 @default.
• W2936132056 creator A5067046900 @default.
• W2936132056 creator A5069277889 @default.
• W2936132056 creator A5074724676 @default.
• W2936132056 creator A5077617951 @default.
• W2936132056 creator A5081049894 @default.
• W2936132056 creator A5084208776 @default.
• W2936132056 creator A5085376424 @default.
• W2936132056 creator A5087667216 @default.
• W2936132056 date "2019-05-01" @default.
• W2936132056 modified "2023-10-06" @default.
• W2936132056 title "Two-year results of a multicenter randomized controlled trial comparing Mechanochemical endovenous Ablation to RADiOfrequeNcy Ablation in the treatment of primary great saphenous vein incompetence (MARADONA trial)" @default.
• W2936132056 cites W1664566016 @default.
• W2936132056 cites W1969682066 @default.
• W2936132056 cites W1991475780 @default.
• W2936132056 cites W2009307687 @default.
• W2936132056 cites W2027134819 @default.
• W2936132056 cites W2032250824 @default.
• W2936132056 cites W2044568464 @default.
• W2936132056 cites W2058017278 @default.
• W2936132056 cites W2093014807 @default.
• W2936132056 cites W2103331094 @default.
• W2936132056 cites W2116736461 @default.
• W2936132056 cites W2130190918 @default.
• W2936132056 cites W2133487160 @default.
• W2936132056 cites W2139214811 @default.
• W2936132056 cites W2147426018 @default.
• W2936132056 cites W2170110656 @default.
• W2936132056 cites W2310565499 @default.
• W2936132056 cites W2399126058 @default.
• W2936132056 cites W2508754946 @default.
• W2936132056 cites W2531394219 @default.
• W2936132056 cites W2563239320 @default.
• W2936132056 cites W2587826972 @default.
• W2936132056 cites W2588992981 @default.
• W2936132056 cites W2594321157 @default.
• W2936132056 cites W2606095980 @default.
• W2936132056 cites W2606412870 @default.
• W2936132056 cites W2606946358 @default.
• W2936132056 cites W2732174638 @default.
• W2936132056 cites W2736382672 @default.
• W2936132056 cites W2748611624 @default.
• W2936132056 cites W2749448471 @default.
• W2936132056 cites W2780906242 @default.
• W2936132056 doi "https://doi.org/10.1016/j.jvsv.2018.12.014" @default.
• W2936132056 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/31000063" @default.
• W2936132056 hasPublicationYear "2019" @default.
• W2936132056 type Work @default.
• W2936132056 sameAs 2936132056 @default.
• W2936132056 citedByCount "46" @default.
• W2936132056 countsByYear W29361320562017 @default.
• W2936132056 countsByYear W29361320562019 @default.
• W2936132056 countsByYear W29361320562020 @default.
• W2936132056 countsByYear W29361320562021 @default.
• W2936132056 countsByYear W29361320562022 @default.
• W2936132056 countsByYear W29361320562023 @default.
• W2936132056 crossrefType "journal-article" @default.
• W2936132056 hasAuthorship W2936132056A5004367806 @default.
• W2936132056 hasAuthorship W2936132056A5021753521 @default.
• W2936132056 hasAuthorship W2936132056A5022225942 @default.
• W2936132056 hasAuthorship W2936132056A5028254994 @default.
• W2936132056 hasAuthorship W2936132056A5029411852 @default.
• W2936132056 hasAuthorship W2936132056A5061498267 @default.
• W2936132056 hasAuthorship W2936132056A5061637031 @default.
• W2936132056 hasAuthorship W2936132056A5065145747 @default.
• W2936132056 hasAuthorship W2936132056A5067046900 @default.
• W2936132056 hasAuthorship W2936132056A5069277889 @default.
• W2936132056 hasAuthorship W2936132056A5074724676 @default.
• W2936132056 hasAuthorship W2936132056A5077617951 @default.
• W2936132056 hasAuthorship W2936132056A5081049894 @default.
• W2936132056 hasAuthorship W2936132056A5084208776 @default.
• W2936132056 hasAuthorship W2936132056A5085376424 @default.
• W2936132056 hasAuthorship W2936132056A5087667216 @default.
• W2936132056 hasBestOaLocation W29361320562 @default.
• W2936132056 hasConcept C126322002 @default.
• W2936132056 hasConcept C141071460 @default.
• W2936132056 hasConcept C159110408 @default.
• W2936132056 hasConcept C168563851 @default.
• W2936132056 hasConcept C2777202286 @default.
• W2936132056 hasConcept C2777377203 @default.
• W2936132056 hasConcept C2777475103 @default.
• W2936132056 hasConcept C2778902805 @default.
• W2936132056 hasConcept C2779480337 @default.
• W2936132056 hasConcept C2779951463 @default.
• W2936132056 hasConcept C535046627 @default.
• W2936132056 hasConcept C71924100 @default.
• W2936132056 hasConceptScore W2936132056C126322002 @default.
• W2936132056 hasConceptScore W2936132056C141071460 @default.
• W2936132056 hasConceptScore W2936132056C159110408 @default.

• next